2015 Chrysler 200 Series C on 2040-cars

Auto blog

The 2020 Chrysler Voyager is a cheap Pacifica minivan

The Voyager is back, baby. Yep, you read that right. FCA is leaning hard on the nostalgia button right now, and the age-old minivan nameplate has rowed its way back from its long voyage (sorry) out to sea. We'll be seeing the Voyager name on a familiar vehicle, though, not a totally new minivan. You're looking at photos of a Pacifica with a Voyager badge on it, because that's essentially what the new Voyager is. Chrysler took the lower trim levels of the Pacifica and decided those would now be Voyagers. Higher trim levels of the Pacifica are still the Pacifica. To quell confusion, just consider the Voyager a budget-conscious Pacifica with a different name. Specifically, both the L and LX trims of Pacifica will be Voyagers, and Chrysler is introducing a fleet-only LXi model with a leatherette (vinyl) interior for mass appeal to rental car companies and businesses with similar needs. Pricing for the 2020 Voyager hasn't been announced yet, but the non-fleet version will probably start right around where the Pacifica L starts now at $28,730. That makes this more of a marketing play than an actual reduction in price. The Voyager is the cheap one, while the Pacifica is the expensive one. Simple as that. Interestingly, FCA still sells significantly more Dodge Grand Caravans than they do Pacificas every month, and it's all down to price. Despite the Pacifica being leagues better than the old Dodge, the average transaction price for the Pacifica in 2019 is over $13,000 more than a Grand Caravan — $38,540 for the Pacifica, versus $24,972 for the Grand Caravan. That makes the Dodge much cheaper than any comparably sized vehicle it competes with and results in the Dodge doubling the Pacifica up on sales regularly. Maybe the introduction of the Voyager could sway some folks in the direction of the new car, rather than being turned off by the high prices of the Pacifica. The feature set for the Voyager is similar to that of the Pacifica-badged models it's replacing. You'll only be able to tell it's a Voyager on the outside from the badge on the liftgate. Chrysler added satellite radio, second-row quad seats and in-floor storage bins to the interior. You'll still get the same Pentastar 3.6-liter V6 and nine-speed automatic transmission in the Voyager, but no plug-in hybrid model will be available. We'll be interested to see how this ultimately affects sales of the excellent Chrysler minivan.

Marchionne completed Fiat-Chrysler deal from a Florida beach

Sergio Marchionne is the CEO of Fiat, which as you may have heard, has finally worked up a deal to finish acquiring the Chrysler Group after months of bargaining with the United Auto Workers and its VEBA healthcare trust, which owned just over 40 percent of the American brand. Where was Marchionne when the deal was finally hammered out? Well, not tucked away in a frigid Detroit board room until the wee hours of the morning.
Nope, one of the largest deals in automotive history was reportedly hammered out on the beach - at the home of a banker, in the Florida resort town of Vero Beach. Marchionne traveled to the home of Alain Lebec, a senior managing director at Brock Capital LLC, one of the advisory companies for the VEBA fund, where both sides met to make final arrangements in the $4.35-billion exchange. The location of the final deal, though, is nearly as remarkable as the pace with which it came about.
According to anonymous sources pinned down by Automotive News Europe, before the meeting, the two sides were meeting in Detroit as recently as December 19, which is where Fiat made one of its final revised offers. Naturally, the VEBA made a counter offer, which led Marchionne to initiate the Vero Beach meeting.

Fiat Chrysler says it did not know about Marchionne's illness

ZURICH/MILAN — Fiat Chrysler said it knew nothing about the medical condition of Sergio Marchionne after a Swiss hospital said on Thursday it had been treating the deceased chief executive for more than a year. "Due to medical privacy, the company had no knowledge of the facts relating to Mr. Marchionne's health," a Fiat Chrysler spokesman said. Questions have been raised about how long Marchionne, who died on Wednesday, was ill and how much the company knew before it made the situation public. Marchionne rescued Fiat and Chrysler from bankruptcy after taking the wheel of the Italian carmaker in 2004 and he multiplied Fiat's value 11 times through 14 years of canny dealmaking. He was due to step down at FCA in April next year. "The company was made aware that Mr. Marchionne had undergone shoulder surgery and released a statement about this," the spokesperson said. "On Friday, July 20, the company was made aware with no detail by Mr. Marchionne's family of the serious deterioration in Mr. Marchionne's condition and that as a result he would be unable to return to work. The company promptly took and announced the appropriate action the following day." Asked whether the scope of the statement included the board and the chairman, the company declined to comment. In emailed comments, Marchionne's family confirmed the companies had not been aware of his health conditions. "At the end of last week FCA was made aware Sergio Marchionne would no longer be able to return to work without mentioning any further details," the family said. The announcement of the death of Marchionne, 66, one of the auto industry's most tenacious and respected CEOs, drew tributes from rivals and tears from his closest colleagues on Wednesday. University Hospital Zurich said earlier on Thursday Marchionne had been treated for a serious illness for more than a year before his death. Marchionne had fallen gravely ill after what the company had described as shoulder surgery at a Zurich hospital. He was replaced as chief executive last weekend after Fiat Chrysler (FCA) said his condition had worsened. "Mr. Sergio Marchionne was a patient at USZ. Due to serious illness, he had been the recipient of recurring treatment for more than a year," the hospital said in a statement. "Although all the options offered by cutting-edge medicine were utilized, Mr.